Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Inclusion Criteria:

* Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB with pleural effusion) and/or metastatic (stage IV) NSCLC
* Progression to first-line therapy for advanced/metastatic NSCLC
* Bi-dimensionally measurable disease (not included in radiation field)
* ECOG performance status of 0-2
* Life expectancy of more than 6 months
* Adequate liver (serum bilirubin \<1.5 times the upper normal limit, AST and ALT \<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \<5 times the upper normal limit in the presence of liver metastases,adequate renal function (serum creatinine \<1.5 times the upper normal limit),and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function
* Signed informed consent

Exclusion Criteria:

* Central nervous system involvement (unless if the patient has being previously irradiated and is clinically stable)
* Presence of a centrally located mass or a tumor mass in close relation to large vessels or a mass with cavitation.
* Surgery or radiation therapy within the last 14 days from study entry
* Active infection
* History of life-threatening hemoptysis / hematemesis, history of thrombosis or use of anti-coagulation therapy
* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmias) or stroke within the previous 6 months or uncontrolled hypertension
* Patients on other experimental treatment protocols
* History of a second primary malignancy (other than basal-cell skin carcinoma or in situ carcinoma of the cervix)
* Psychiatric illness or social situation that would preclude study compliance
* Pregnant or lactating women